https://clinicaltrials.gov/study/NCT06249919
A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients
Clinical Trials
Intra-Tympanic Steroid With PRP Combination in Sensorineural Hearing Loss and Tinnitus.
CATEGORY:
Clinical Trials
TITLE:
Intra-Tympanic Steroid With PRP Combination in Sensorineural Hearing Loss and Tinnitus.
INTERVENTION/TREATMENT:
PHASE:
DESCRIPTION:
Conditions : Sensorineural Hearing Loss; Tinnitus
Intervention : Drug: Combination Solution
Sponsor : CMH RWP Combined Military Hospital RWP: Rawalpindi
Not yet recruiting
ID:
NCT06025097
STATUS:
DATE – FIRST POSTED:
Wed, 06 Sep 2023 12:00:00 EDT
DATE – LAST UPDATE POSTED:
09/06/23 08:50AM
DATE – RETRIEVED:
09/06/23 08:50AM
LINK – STUDY HISTORY:
https://clinicaltrials.gov/ct2/history/NCT06025097
LINK – STUDY RECORD:
https://clinicaltrials.gov/ct2/show/NCT06025097
REFERENCE:
Hearing Loss Treatment Report, Urgent Research
Assessment of The Efficacy of Intratympanic Platelet Rich Plasma for Treatment of Sensorineural Hearing Loss.
CATEGORY:
Clinical Trials
TITLE:
Assessment of The Efficacy of Intratympanic Platelet Rich Plasma for Treatment of Sensorineural Hearing Loss.
INTERVENTION/TREATMENT:
PHASE:
DESCRIPTION:
Conditions : Hearing Loss, Sudden; Hearing Loss, Sensorineural; Hearing Loss
Interventions : Biological: Platelet Rich Plasma; Drug: local anesthesia in external auditory canal; Procedure: Intratympanic Injection
Sponsor : Assiut University
Not yet recruiting
ID:
NCT05786378
STATUS:
DATE – FIRST POSTED:
Mon, 27 Mar 2023 12:00:00 EDT
DATE – LAST UPDATE POSTED:
03/27/23 02:34PM
DATE – RETRIEVED:
03/27/23 02:34PM
LINK – STUDY HISTORY:
https://clinicaltrials.gov/ct2/history/NCT05786378
LINK – STUDY RECORD:
https://clinicaltrials.gov/ct2/show/NCT05786378
REFERENCE:
Hearing Loss Treatment Report, Urgent Research
FX-322 in Adults With Acquired Sensorineural Hearing Loss
CATEGORY:
Clinical Trials
TITLE:
FX-322 in Adults With Acquired Sensorineural Hearing Loss
INTERVENTION/TREATMENT:
PHASE:
DESCRIPTION:
Conditions : Hearing Loss, Sensorineural; Noise Induced Hearing Loss; Sudden Hearing Loss
Interventions : Drug: FX-322; Drug: Placebo
Sponsor : Frequency Therapeutics
Recruiting
ID:
NCT05086276
STATUS:
DATE – FIRST POSTED:
Wed, 20 Oct 2021 12:00:00 EDT
DATE – LAST UPDATE POSTED:
10/20/21 06:28AM
DATE – RETRIEVED:
10/20/21 06:28AM
LINK – STUDY HISTORY:
https://clinicaltrials.gov/ct2/history/NCT05086276
LINK – STUDY RECORD:
https://clinicaltrials.gov/ct2/show/NCT05086276
REFERENCE:
Hearing Loss Treatment Report, Urgent Research
A Trial of LY3056480 in Patients With SNLH
CATEGORY:
Clinical Trials
TITLE:
A Trial of LY3056480 in Patients With SNLH
INTERVENTION/TREATMENT:
PHASE:
DESCRIPTION:
Condition : Sensorineural Hearing Loss
Intervention : Drug: LY3056480
Sponsor : Audion Therapeutics BV
Not yet recruiting
ID:
NCT05061758
STATUS:
DATE – FIRST POSTED:
Thu, 30 Sep 2021 12:00:00 EDT
DATE – LAST UPDATE POSTED:
09/30/21 05:28PM
DATE – RETRIEVED:
09/30/21 05:28PM
LINK – STUDY HISTORY:
https://clinicaltrials.gov/ct2/history/NCT05061758
LINK – STUDY RECORD:
https://clinicaltrials.gov/ct2/show/NCT05061758
REFERENCE:
Hearing Loss Treatment Report, Urgent Research
FX-322 in Adults With Severe Sensorineural Hearing Loss
CATEGORY:
Clinical Trials
TITLE:
FX-322 in Adults With Severe Sensorineural Hearing Loss
INTERVENTION/TREATMENT:
PHASE:
DESCRIPTION:
Conditions : Hearing Loss, Sensorineural; Noise Induced Hearing Loss; Sudden Hearing Loss
Interventions : Drug: FX-322; Other: Placebo
Sponsor : Frequency Therapeutics
Recruiting
ID:
NCT04629664
STATUS:
DATE – FIRST POSTED:
Mon, 16 Nov 2020 12:00:00 EST
DATE – LAST UPDATE POSTED:
07/06/21 07:55AM
DATE – RETRIEVED:
07/06/21 07:55AM
LINK – STUDY HISTORY:
https://clinicaltrials.gov/ct2/history/NCT04629664
LINK – STUDY RECORD:
https://clinicaltrials.gov/ct2/show/NCT04629664
REFERENCE:
Hearing Loss Treatment Report, Urgent Research
Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss [Completed]
CATEGORY:
Clinical Trials
TITLE:
Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss
INTERVENTION/TREATMENT:
PHASE:
DESCRIPTION:
Condition : Sensorineural Hearing Loss
Interventions : Drug: PIPE-505; Drug: Diluent alone
Sponsor : Pipeline Therapeutics, Inc.
Completed
ID:
NCT04462198
STATUS:
DATE – FIRST POSTED:
Wed, 08 Jul 2020 12:00:00 EDT
DATE – LAST UPDATE POSTED:
06/24/21 11:34AM
DATE – RETRIEVED:
06/24/21 11:34AM
LINK – STUDY HISTORY:
https://clinicaltrials.gov/ct2/history/NCT04462198
LINK – STUDY RECORD:
https://clinicaltrials.gov/ct2/show/NCT04462198
REFERENCE:
Hearing Loss Treatment Report, Urgent Research
OTO-413 in Subjects With Speech-in-Noise Hearing Impairment
CATEGORY:
Clinical Trials
TITLE:
OTO-413 in Subjects With Speech-in-Noise Hearing Impairment
INTERVENTION/TREATMENT:
PHASE:
DESCRIPTION:
Condition : Sensorineural Hearing Loss
Interventions : Drug: OTO-413; Drug: Placebo
Sponsor : Otonomy, Inc.
Recruiting
ID:
NCT04129775
STATUS:
DATE – FIRST POSTED:
Thu, 17 Oct 2019 12:00:00 EDT
DATE – LAST UPDATE POSTED:
06/18/21 05:20PM
DATE – RETRIEVED:
06/18/21 05:20PM
LINK – STUDY HISTORY:
https://clinicaltrials.gov/ct2/history/NCT04129775
LINK – STUDY RECORD:
https://clinicaltrials.gov/ct2/show/NCT04129775
FX-322 in Sensorineural Hearing Loss [Completed]
CATEGORY:
Clinical Trials
TITLE:
FX-322 in Sensorineural Hearing Loss
INTERVENTION/TREATMENT:
PHASE:
DESCRIPTION:
Condition : Sensorineural Hearing Loss
Interventions : Drug: FX-322; Drug: Placebo
Sponsor : Frequency Therapeutics
Completed
ID:
NCT03616223
STATUS:
DATE – FIRST POSTED:
Mon, 06 Aug 2018 12:00:00 EDT
DATE – LAST UPDATE POSTED:
03/30/21 06:51AM
DATE – RETRIEVED:
03/30/21 06:51AM
LINK – STUDY HISTORY:
https://clinicaltrials.gov/ct2/history/NCT03616223
LINK – STUDY RECORD:
https://clinicaltrials.gov/ct2/show/NCT03616223
Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss
CATEGORY:
Clinical Trials
TITLE:
Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss
INTERVENTION/TREATMENT:
PHASE:
DESCRIPTION:
Condition : Sensorineural Hearing Loss
Interventions : Drug: PIPE-505; Drug: Diluent alone
Sponsor : Pipeline Therapeutics, Inc.
Recruiting
ID:
NCT04462198
STATUS:
DATE – FIRST POSTED:
Wed, 08 Jul 2020 12:00:00 EDT
DATE – LAST UPDATE POSTED:
10/14/20 08:47PM
DATE – RETRIEVED:
10/14/20 08:47PM
LINK – STUDY HISTORY:
https://clinicaltrials.gov/ct2/history/NCT04462198
LINK – STUDY RECORD:
https://clinicaltrials.gov/ct2/show/NCT04462198
Verification of the Efficacy/Safety of the Dual Drug Delivery for Hearing Loss
https://clinicaltrials.gov/ct2/show/NCT04766853
Verification of the Efficacy/Safety of the Dual Drug Delivery for Hearing Loss
Brief Summary:
This study is a prospective, randomized pilot study. To verify an efficacy and safety of the dual drug injectable delivery vehicle, patients who have not responded to the existing standard treatment will be enrolled. Hearing test and endoscopy of tympanic membrane will be conducted after intratympanic treatment for evaluation.
Condition or disease Intervention/treatment Phase
Hearing Loss, Sudden
Hearing Loss Ototoxic
Hearing Loss, Noise-Induced
Meniere Disease
Drug: Dexamethasone
Drug: Hyaluronic acid
Phase 1
Phase 2
Study Design
Go to sections
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 26 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Verification of the Efficacy / Safety of the Dual Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss (Pilot Study)
Estimated Study Start Date : March 2021
Estimated Primary Completion Date : February 2022
Estimated Study Completion Date : February 2022
FX-322 in Adults With Age-Related Sensorineural Hearing Loss
CATEGORY:
Clinical Trials
TITLE:
FX-322 in Adults With Age-Related Sensorineural Hearing Loss
INTERVENTION/TREATMENT:
PHASE:
DESCRIPTION:
Conditions : Presbycusis; Hearing Loss, Sensorineural; Noise Induced Hearing Loss; Sudden Hearing Loss
Interventions : Drug: FX-322; Other: placebo
Sponsor : Frequency Therapeutics
Recruiting
ID:
NCT04601909
STATUS:
DATE – FIRST POSTED:
Mon, 26 Oct 2020 12:00:00 EDT
DATE – LAST UPDATE POSTED:
10/26/20 07:11AM
DATE – RETRIEVED:
10/26/20 07:11AM
LINK – STUDY HISTORY:
https://clinicaltrials.gov/ct2/history/NCT04601909
LINK – STUDY RECORD:
https://clinicaltrials.gov/ct2/show/NCT04601909
Efficacy of SENS-401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss
https://clinicaltrials.gov/ct2/show/NCT03603314?type=Intr&cond=Hearing+Loss&lupd_s=05%2F05%2F2020&lupd_d=14&sort=nwst
Condition : Severe Sudden Sensorineural Hearing Loss
Interventions : Drug: SENS-401; Other: Placebo Oral Tablet
Sponsor : Sensorion
Recruiting
Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss
NCT03603314
Fri, 27 Jul 2018 12:00:00 EDT
Last Update Posted: 05/19/20 06:40AM
FX-322 in Adults With Stable Sensorineural Hearing Loss
New item in Clinical Trial category found.
TITLE:
FX-322 in Adults With Stable Sensorineural Hearing Loss
DESCRIPTION:
Conditions : Sensorineural Hearing Loss; Noise Induced Hearing Loss; Sudden Sensorineural Hearing Loss
Interventions : Drug: FX-322; Drug: Placebo
Sponsor : Frequency Therapeutics
Active, not recruiting
ID:
NCT04120116
FIRST POSTED:
Wed, 09 Oct 2019 12:00:00 EDT
LAST UPDATE POSTED:
10/08/20 07:05AM
RECRUITMENT STATUS:
recruiting
INTERVENTION/DRUG:
FX-322
SOURCE LINK:
https://clinicaltrials.gov/ct2/show/NCT04120116?type=Intr&cond=Sensorineural+Hearing+Loss&phase=0124&lupd_s=10%2F07%2F2020&lupd_d=1&sort=nwst
LINK:
https://clinicaltrials.gov/ct2/show/NCT04120116
OTO-413 in Subjects With Speech-in-Noise Hearing Impairment
https://clinicaltrials.gov/ct2/show/NCT04129775?type=Intr&cond=Hearing+Loss&lupd_s=10%2F03%2F2019&lupd_d=14&sort=nwst
Condition : Sensorineural Hearing Loss
Interventions : Drug: OTO-413; Drug: Placebo
Sponsor : Otonomy, Inc.
Recruiting
OTO-413 in Subjects With Speech-in-Noise Hearing Impairment
NCT04129775
Thu, 17 Oct 2019 12:00:00 EDT
Last Update Posted: 10/17/19 08:21AM
https://clinicaltrials.gov/ct2/show/NCT04129775
OTO-413 in Subjects With Speech-in-Noise Hearing Impairment
Updated: September 14, 2020
Active, not recruiting
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-413 Given as a Single Intratympanic Injection in Subjects With Speech-in-noise Hearing Impairment
Actual Study Start Date : October 1, 2019
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : October 2020
Protective Effects of EPI-743 on Noise-Induced Hearing Loss [Completed]
https://clinicaltrials.gov/ct2/show/NCT02257983?type=Intr&cond=Hearing+Loss&lupd_s=08%2F17%2F2020&lupd_d=14&sort=nwst
Condition : Noise-induced Hearing Loss
Interventions : Drug: EPI-743; Drug: Placebo
Sponsor : PTC Therapeutics
Completed
Protective Effects of EPI-743 on Noise-Induced Hearing Loss
NCT02257983
Tue, 07 Oct 2014 12:00:00 EDT
Last Update Posted: 08/31/20 07:19AM
Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment [Terminated]
https://clinicaltrials.gov/ct2/show/NCT02809118?type=Intr&cond=Hearing+Loss&lupd_s=07%2F24%2F2020&lupd_d=14&sort=nwst
Condition : Hearing Loss, Idiopathic Sudden Sensorineural
Interventions : Drug: AM-111 0.4 mg/ml; Drug: AM-111 0.8 mg/ml; Other: Placebo
Sponsor : Auris Medical, Inc.
Terminated
Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment
NCT02809118
Wed, 22 Jun 2016 12:00:00 EDT
Last Update Posted: 08/07/20 06:52AM
Phase 2a Study of FX-322 Administered by Intratympanic Injection in Adults With Stable Sensorineural Hearing Loss
https://clinicaltrials.gov/ct2/show/NCT04120116?type=Intr&cond=Hearing+Loss&lupd_s=09%2F25%2F2019&lupd_d=14&sort=nwst
Conditions : Sensorineural Hearing Loss; Noise Induced Hearing Loss; Sudden Sensorineural Hearing Loss
Interventions : Drug: FX-322; Drug: Placebo
Sponsor : Frequency Therapeutics
Recruiting
FX-322 in Adults With Stable Sensorineural Hearing Loss
NCT04120116
Wed, 09 Oct 2019 12:00:00 EDT
Last Update Posted: 10/09/19 10:49AM
High Dose Oral Steroids in Sudden Sensorineural Hearing Loss [Suspended] (On hold due to COVID-19 outbreak)
https://clinicaltrials.gov/ct2/show/NCT03255473
High Dose Oral Steroids in Sudden Sensorineural Hearing Loss
Study Type : Interventional
Estimated Enrollment : 208 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Compare hearing outcomes between treatment with dexamethasone versus prednisone in participants who have been diagnosed with unilateral SSNHL within six weeks, and compare side effect profiles between the two treatment regimens of either dexamethasone or prednisone.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: High Dose Oral Steroids in Sudden Sensorineural Hearing Loss
Actual Study Start Date : August 30, 2017
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : February 2020
Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL [Completed]
https://clinicaltrials.gov/ct2/show/NCT03331627?type=Intr&cond=Hearing+Loss&lupd_s=03%2F27%2F2019&lupd_d=14&sort=nwst
Condition : Acute Hearing Loss
Intervention : Drug: STR001-IT and STR001-ER
Sponsor : Strekin AG
Recruiting
Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL
NCT03331627
Mon, 06 Nov 2017 12:00:00 EST
Last Update Posted: 04/10/19 08:35AM
Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss [Completed]
https://clinicaltrials.gov/ct2/show/NCT02132130?type=Intr&cond=Hearing+Loss&lupd_s=04%2F29%2F2019&lupd_d=14&sort=nwst
Condition : Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss
Intervention : Drug: CGF166
Sponsor : Novartis Pharmaceuticals
Recruiting
Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss
NCT02132130
Wed, 07 May 2014 12:00:00 EDT
Last Update Posted: 05/13/19 07:50AM
Intratympanic Steroids for Sudden Hearing Loss
https://clinicaltrials.gov/ct2/show/NCT04129697?type=Intr&cond=Hearing+Loss&lupd_s=10%2F03%2F2019&lupd_d=14&sort=nwst
Condition : Dexamethasone or Methylprednisolone; Sudden Hearing Loss; Intratympanic Steroid
Intervention : Drug: Dexamethasone or Methylprednisolone
Sponsor : Second Affiliated Hospital, School of Medicine, Zhejiang University
Not yet recruiting
Intratympanic Steroids for Sudden Hearing Loss
NCT04129697
Thu, 17 Oct 2019 12:00:00 EDT
Last Update Posted: 10/17/19 08:21AM
Vestibular Prognosis Assessment of ISSNHL With Vestibular Dysfunction Treated With Oral or Intratympanic Glucocorticoids
https://clinicaltrials.gov/ct2/show/NCT03974867?type=Intr&cond=Hearing+Loss&lupd_s=05%2F22%2F2019&lupd_d=14&sort=nwst
Conditions : Vestibular Vertigo; Sudden Hearing Loss
Interventions : Drug: Prednisone 5Mg Tab; Drug: Methylprednisolone 40 mg
Sponsor : Eye & ENT Hospital of Fudan University
Not yet recruiting
Vestibular Prognosis Assessment of ISSNHL With Vestibular Dysfunction Treated With Oral or Intratympanic Glucocorticoids
NCT03974867
Wed, 05 Jun 2019 12:00:00 EDT
Last Update Posted: 06/05/19 07:52AM
Phase 3 Clinical Trial: D-methionine to Reduce Noise-Induced Hearing Loss (NIHL) [Terminated]
https://clinicaltrials.gov/ct2/show/NCT02903355?type=Intr&cond=Hearing+Loss&lupd_s=04%2F15%2F2019&lupd_d=14&sort=nwst
Condition : Noise-induced Hearing Loss
Interventions : Drug: D-methionine; Drug: Placebo
Sponsor : Southern Illinois University
Terminated
Phase 3 Clinical Trial: D-methionine to Reduce Noise-Induced Hearing Loss (NIHL)
NCT02903355
Fri, 16 Sep 2016 12:00:00 EDT
Last Update Posted: 04/29/19 08:25AM
A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss (PANIHL)
https://clinicaltrials.gov/ct2/show/NCT02779192
A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss (PANIHL)